BGB-A317-302

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-302

ClinicalTrials.gov ID info

EudraCT Number info

2017-003699-30

China Drug Trials ID info

CTR20171026

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan